Vincerx Pharma
260 Sheridan Ave
Suite 400
Palo Alto
California
94306
United States
Website: http://www.vincerx.com/
39 articles with Vincerx Pharma
-
Vincerx Pharma Reports Fourth Quarter and Full Year 2022 Financial Results and Provides a Corporate Update
3/28/2023
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2022, and provided a corporate update.
-
Vincerx Pharma Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2023
3/14/2023
Vincerx Pharma, Inc. (Nasdaq: VINC) today announced four poster presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2023, being held virtually and at the Orange County Convention Center in Orlando, Florida from April 14-19, 2023.
-
Vincerx Pharma to Participate at the SVB Securities Global Biopharma Conference
2/6/2023
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that Vincerx’s management team will present the company’s corporate overview and participate in one-on-one investor meetings at the SVB Securities Global Biopharma Conference, to be held virtually from February 14-16, 2023.
-
Vincerx Pharma Announces FDA Safe to Proceed Letter for Investigational New Drug (IND) Application for its αVβ3 Small Molecule-Drug Conjugate (SMDC) VIP236
12/13/2022
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has provided a safe to proceed letter and cleared the IND application for VIP236, the Company’s front-runner SMDC for the treatment of advanced solid tumors.
-
Vincerx Pharma Provides American Society of Hematology Annual Meeting 2022 Poster Highlights on Enitociclib in Multiple Tumor Types
12/12/2022
Vincerx Pharma, Inc. (Nasdaq: VINC) today announced two poster presentations of preclinical and clinical data on the Company’s lead asset, enitociclib (also known as VIP152) at the 64th American Society of Hematology (ASH) Annual Meeting 2022 and additional data-related updates in the enitociclib program.
-
Vincerx Pharma Presents Preclinical Data on VIP943 in Acute Myeloid Leukemia Models at the 64th American Society of Hematology Annual Meeting 2022
12/11/2022
Vincerx Pharma, Inc. announced a poster presentation of preclinical data of Vincerx’s proprietary payload and linker technology and VIP943, the Company’s internalizing ADC targeting CD123, at the 64th American Society of Hematology Annual Meeting 2022.
-
Vincerx Pharma Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
11/10/2022
Vincerx Pharma, Inc. reported financial results for the quarter ended September 30, 2022 and provided a corporate update.
-
Vincerx Pharma Announces Upcoming Poster Presentations at the 64th American Society of Hematology (ASH) Annual Meeting 2022
11/3/2022
Vincerx Pharma, Inc. announced three poster presentations at the upcoming 64th American Society of Hematology Annual Meeting 2022, being held virtually and in New Orleans, Louisiana from December 10-13, 2022.
-
Vincerx Pharma Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
8/11/2022
Vincerx Pharma, Inc., a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, reported financial results for the second quarter ended June 30, 2022 and provided a corporate update.
-
The life science industry is growing rapidly, and many companies have announced expansions and job creation. Still, others have been forced to cut costs and slash jobs. For that and more, continue reading.
-
Vincerx Pharma Presents Preclinical and Clinical Data on PTEFb/CDK9 Inhibitor VIP152 in Lymphoma at the European Hematology Association 2022 Congress
6/10/2022
Vincerx Pharma, Inc. today announced a poster presentation of preclinical and clinical data on VIP152, the Company’s PTEFb/CDK9 inhibitor, at the European Hematology Association (EHA) 2022 Congress, being held virtually and in Vienna, Austria from June 9-12, 2022.
-
Amarin and Vincerx Pharma intend to restructure their financial strategies and lessen operational costs by trimming their employee rosters.
-
Vincerx Pharma Provides Key Strategic Update
6/6/2022
Vincerx Pharma, Inc. announced an update to its strategic priorities and the streamlining and realignment of resources to support its key value-generating indications and programs and extend its estimated cash runway into late 2024.
-
Vincerx Pharma Reports First Quarter 2022 Financial Results and Provides a Corporate Update
5/12/2022
Vincerx Pharma, Inc. reported financial results for the first quarter ended March 31, 2022 and provided a corporate update.
-
Vincerx Pharma Reports Fourth Quarter and Full Year 2021 Financial Results and Provides a Corporate Update
3/29/2022
Vincerx Pharma, Inc. (Nasdaq: VINC), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported financial results for the fourth quarter and full year ended December 31, 2021, and provided a corporate update.
-
Vincerx Pharma to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
2/9/2022
Vincerx Pharma, Inc. announced that Vincerx’s management team will participate in a fireside chat and one-on-one investor meetings at the SVB Leerink 11th Annual Global Healthcare Conference, to be held virtually February 14-18, 2022.
-
Vincerx Pharma Publishes Preclinical Data Demonstrating Therapeutic Potential of Small Molecule-Drug Conjugate VIP236 in the Journal Cancers
2/3/2022
Vincerx Pharma, Inc. today announced the publication of a peer-reviewed article.
-
Clinical Catch-Up: December 11-17
12/20/2021
It was an enormously busy week with plenty of announcements from the American Society of Hematology meeting and numerous companies working to get the news out ahead of the holidays and year-end. Here’s a look. -
Vincerx Pharma Announces First Patient Dosed in Phase 1 Dose-Escalation Study of VIP152 in Relapsed or Refractory Chronic Lymphocytic Leukemia or Richter Syndrome
12/17/2021
Vincerx Pharma, Inc. today announced that the first patient has been dosed in the Company’s Phase 1 dose-escalation study of VIP152 in relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) or Richter Syndrome (RS).
-
Vincerx Pharma Presents Data on PTEFb/CDK9 Inhibitor VIP152 in DLBCL and CLL at the 63rd American Society of Hematology Annual Meeting
12/11/2021
Vincerx Pharma, Inc. announced data on VIP152, the Company’s PTEFb/CDK9 inhibitor, in high-grade B-cell lymphoma, formerly referred to as double-hit lymphoma, and chronic lymphocytic leukemia, in two presentations at the 63rd American Society of Hematology Annual Meeting held December 11-14, 2021 in Atlanta GA.